Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Clinical Impact of Multiple-Clip Implantation for Residual Mitral Regurgitation After Transcatheter Edge-to-Edge Repair.

BACKGROUND Residual moderate or greater mitral regurgitation (MR) after transcatheter edge-to-edge repair is strongly associated with adverse clinical outcomes. However, the prognostic impact of implanting additional clips in patients with significant residual MR after the first clip remains uncertain. We evaluated the...

T. Nagasaka, V. Patel, Kazuki Suruga et al. · 0 citations
Open access Sep 2026

Long-Term Outcomes of Contemporary Balloon-Expandable TAVR in Bicuspid Aortic Valve: A Propensity-Matched Comparison to Tricuspid.

BACKGROUND Limited data are available comparing clinical outcomes between bicuspid and tricuspid patients following transcatheter aortic valve replacement (TAVR). OBJECTIVES This study sought to investigate 5-year clinical outcomes in patients with severe aortic stenosis following TAVR with contemporary balloon-expan...

Kazuki Suruga, V. Patel, H. Shitan et al. · 1 citation
Open access Aug 2026

Early Multicenter Outcomes of Dedicated Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device‐Associated Pure Aortic Regurgitation

ABSTRACT Background Aortic regurgitation (AR) is a frequent and clinically relevant complication in patients with left ventricular assist devices (LVAD), impairing circulatory support and worsening outcomes. Surgical aortic valve replacement often carries prohibitive risk in this population, while conventional transcat...

H. Hinkov, Sara Yousefzada, I. Just et al. · 0 citations
Open access Sep 2026

Five-Year Follow-Up of Transcatheter Aortic Valve Replacement With Self-Expanding Intra-Annular Versus Commercially Available Valves.

In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.

Raj R. Makkar, Wen Cheng, Ron Waksman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.